NEW

Butterfly Files Motion to Dismiss Claims in FUJIFILM Sonosite Legal Action

Butterfly Network Inc. has filed a motion to dismiss claims and specific patents from a complaint for patent infringement lawsuit filed on March 9, 2022, by FUJIFILM Sonosite Inc. Butterfly believes the lawsuit alleging infringement of U.S. Patent Nos. 7,169,108;...

ARTIS icono ceiling Angiography System Earns FDA Clearance

Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the ARTIS icono ceiling, a ceiling-mounted angiography system designed for a wide range of routine and advanced procedures in interventional radiology (IR) and cardiology. The...

New Fixed X-ray System Brings ‘Personal Assistant’ to Radiology Departments

GE Healthcare released its most advanced fixed X-ray system yet, the next-generation Definium 656 HD. Leading GE Healthcare’s portfolio of fixed X-ray products, this latest generation of the overhead tube suspension (OTS) system delivers consistent, highly automated,...

Exo Acquires Medo AI

Exo (pronounced “echo”), a pioneering health information and medical devices company, has announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use. By integrating Medo’s...

Bracco Diagnostics Inc. Introduces New CardioGen-82 Infusion System

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., has announced the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). This next-generation infusion system model will replace the company’s current infusion system.

Vittorio Puppo, president and CEO of Bracco Diagnostics Inc., said, “The new infusion system exemplifies Bracco’s significant investment in the cardiac PET imaging modality and is the culmination of thoughtful design and feedback from health care providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve.”

Developed with clinicians and nuclear medicine technologists in mind, the new infusion system is elegantly designed with intuitive and ergonomic details that provide easy access to all system components while minimizing radiation exposure for staff and patients.

Other smart features enable workflow efficiencies that can save nearly an hour at the beginning of each day of patient imaging and eliminate manual record keeping. A choice of dosing options and other protocol parameters make changes in scheduling and patient needs easy to accommodate.

“Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989,” said Kim McDaniel, senior director, nuclear medicine sales and market support. “Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease, and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide.”

See full Prescribing Information for CARDIOGEN-82 (Rubidium Rb 82 Generator) including boxed WARNING at https://imaging.bracco.com/us-en/products/nuclear-medicine-radiopharmaceuticals/cardiogen-82.

For additional information, visit imaging.bracco.com/us-en.

Previous

Next

Submit a Comment

Your email address will not be published.